Back to User profile » Dr Gerhard Müller-Schwefe
Papers published by Dr Gerhard Müller-Schwefe:
Beyond Methodological Considerations: Clinical Implications of Real-World Evidence from the CARE Study [Response to Letter]
Überall MA, Müller-Schwefe PCG, Küster MA, Müller-Schwefe GHH
Journal of Pain Research 2026, 19:611585
Published Date: 27 March 2026
CARE – A Retrospective, Dual-Cohort, 24-Week Real-World Study from the German Pain e-Registry on the Effectiveness and Safety of CBD-Dominant Oral Cannabis Extracts versus THC/Dronabinol in Older Patients with Chronic Pain
Überall MA, Müller-Schwefe PCG, Küster MA, Müller-Schwefe GH
Journal of Pain Research 2026, 19:551457
Published Date: 7 March 2026
Safety, Tolerability, and Efficacy of Hox Alpha, a Dry Extract from Stinging Nettle Leaves versus OTC NSAIDs in Osteoarthritis: A Retrospective, Propensity-Matched 12-Week Analysis from the German Pain e-Registry (SIPHARO Study)
Überall MA, Küster MA, Müller-Schwefe PCG, Müller-Schwefe GH
Journal of Pain Research 2026, 19:546747
Published Date: 19 February 2026
Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
Ueberall MA, Essner U, Vila Silván C, Mueller-Schwefe GHH
Journal of Pain Research 2022, 15:267-286
Published Date: 2 February 2022
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
Ueberall MA, Essner U, Mueller-Schwefe GHH
Journal of Pain Research 2019, 12:1577-1604
Published Date: 20 May 2019
Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations
Ueberall MA, Mueller-Schwefe GHH
Journal of Pain Research 2016, 9:1001-1020
Published Date: 11 November 2016
Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials
Ueberall MA, Mueller-Schwefe GH, Wigand R, Essner U
Journal of Pain Research 2016, 9:941-961
Published Date: 4 November 2016
Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
Ueberall MA, Eberhardt A, Mueller-Schwefe GHH
International Journal of General Medicine 2016, 9:39-51
Published Date: 24 February 2016
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids [Corrigendum]
Ueberall MA, Mueller-Schwefe GHH
Journal of Pain Research 2015, 8:807-808
Published Date: 12 November 2015
Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids
Ueberall MA, Mueller-Schwefe GHH
Journal of Pain Research 2015, 8:459-475
Published Date: 10 August 2015